# US 2025/0375437 A1 · Methods for improving cognitive function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375437 A1
- Document ID: US20250375437A1
- Status: Published application
- Kind: A1
- Application number: 18/733,862
- Filed: 2024-06-05
- Published: 2025-12-11
- Earliest claimed: 2024-06-05
- Inventors: RU-BAND LU
- Web page: https://patentgrep.com/patent/US20250375437A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/19: Carboxylic acids, e.g. valproic acid (salicylic acid A61K31/60)
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for improving cognitive function of a subject which includes administering a composition containing dextromethorphan or valproic acid to the subject in need thereof. The composition containing the dextromethorphan is used for improving the sustained attention of the subject. The composition containing the valproic acid is used for improving the memory of the subject.

## Claims

### Claim 1

A method for improving sustained attention of a subject suffering from attention deficit comprising administering a composition containing dextromethorphan to the subject suffering from attention deficit.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject suffers from childhood-onset fluency disorder.

### Claim 3 (depends on 2)

The method of claim 2, wherein the childhood-onset fluency disorder comprises stuttering.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject suffers from a psychiatric disorder, or a disease related to neuronal apoptosis or neurodegeneration.

### Claim 5 (depends on 4)

The method of claim 4, wherein the psychiatric disorder comprises bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, or depression.

### Claim 6 (depends on 4)

The method of claim 4, wherein the disease related to neuronal apoptosis or neurodegeneration comprises stroke, alzheimer's disease, huntington's disease, parkinson's disease, pick's disease, creutzfeldt-jakob's disease, amyotrophic lateral sclerosis-parkinsonism-dementia complex, wilson's disease, multiple sclerosis, progressive supranuclear palsy, corticobasal degeneration, dementia, amyotrophic lateral sclerosis, epilepsy, transient ischemic attack, myocardial ischemia, head injury, spinal cord injury, or hypoxia.

### Claim 7 (depends on 1)

The method of claim 1, wherein the effective amount of the dextromethorphan ranges from 0.1 to 30 mg/day.

### Claim 8

A method for improving memory of a subject suffering from memory disorder comprising administering a composition containing valproic acid or a pharmaceutically acceptable salt thereof to the subject suffering from memory disorder.

### Claim 9 (depends on 8)

The method of claim 8, wherein the pharmaceutically acceptable salt of the valproic acid comprises sodium valproate.

### Claim 10 (depends on 8)

The method of claim 8, wherein the composition further comprises dextromethorphan.

### Claim 11 (depends on 8)

The method of claim 8, wherein the memory comprises verbal memory, spatial memory, immediate memory, delayed memory, and working memory.

### Claim 12 (depends on 8)

The method of claim 8, wherein the subject suffers from childhood-onset fluency disorder.

### Claim 13 (depends on 12)

The method of claim 12, wherein the childhood-onset fluency disorder comprises stuttering.

### Claim 14 (depends on 8)

The method of claim 8, wherein the subject suffers from a psychiatric disorder, or a disease related to neuronal apoptosis or neurodegeneration.

### Claim 15 (depends on 14)

The method of claim 14, wherein the psychiatric disorder comprises bipolar disorder, schizophrenia, attention deficit hyperactivity disorder, or depression.

### Claim 16 (depends on 14)

The method of claim 14, wherein the disease related to neuronal apoptosis or neurodegeneration comprises stroke, alzheimer's disease, huntington's disease, parkinson's disease, pick's disease, creutzfeldt-jakob's disease, amyotrophic lateral sclerosis-parkinsonism-dementia complex, wilson's disease, multiple sclerosis, progressive supranuclear palsy, corticobasal degeneration, dementia, amyotrophic lateral sclerosis, epilepsy, transient ischemic attack, myocardial ischemia, head injury, spinal cord injury, or hypoxia.

### Claim 17 (depends on 8)

The method of claim 8, wherein the effective amount of the valproic acid ranges from 500 to 2500 mg/day.
